Abstract
ObjectiveTo assess pathological characteristics, clinical features and outcomes of patients diagnosed with peripheral zone (PZ) and transition zone (TZ) prostate cancer after prostatectomy.Methods and analysisWe systematically reviewed PubMed, EMBASE and MEDLINE. Primary endpoints were biochemical relapse-free survival (bRFS) and distant metastases rate; secondary endpoints included clinical and pathological features.ResultsTen retrospective cohort studies were identified, six reported HRs for bRFS between PZ and TZ tumours. Patients with TZ tumours had significantly better bRFS (pooled HR 0.57 (0.47, 0.68)) than those with PZ tumours. Two studies reported a lower proportion of distant metastasis in patients diagnosed with TZ tumours compared with PZ tumours (1.5% vs 4.9% (median follow-up 7.0 years) and 0% vs 5% (median follow-up 7.8 years)). PZ tumours presented higher Gleason group and T staging more frequently, while TZ tumours were associated with higher prostate specific antigen levels at diagnosis.ConclusionPZ tumours were associated with poorer prognostic clinical features and outcomes. Despite adjusting for poor prognostic clinical features, PZ tumours consistently showed worse clinical outcomes than TZ tumours. Our systematic review underscores the need for further research comparing PZ and TZ prostate cancer to understand the underlying differences and refine clinical practice.
Funder
CRUK Clinical Training Award -Manchester Centre of Excellence
Cancer Research UK Manchester Centre
Prostate Cancer UK - Movember Prostate Cancer Centre of Excellence
Prostate Cancer Foundation-John Black Charitable Foundation Young Investigator
Reference49 articles.
1. Clarke NW , Armstrong AJ , Thiery-Vuillemin A , et al . Abiraterone and Olaparib for metastatic Castration-resistant prostate cancer. NEJM Evid 2022;1. doi:10.1056/EVIDoa2200043
2. Rucaparib or physician’s choice in metastatic prostate cancer;Fizazi;N Engl J Med,2023
3. Olaparib for Metastatic Castration-Resistant Prostate Cancer
4. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
5. Schaeffer EM , Srinivas S , Adra N , et al . NCCN guidelines® insights: prostate cancer, version 1.2023: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2022:1288–98.